Synthesis, DFT Calculations, In Silico Studies, and Antimicrobial Evaluation of Benzimidazole-Thiadiazole Derivatives
Ayşen Işık, Ulviye Acar Çevik, Arzu Karayel, Iqrar Ahmad, Harun Patel, İsmail Çelik, Ülküye Dudu Gül, Gizem Bayazıt, Hayrani Eren Bostancı, Ahmet Koçak, Yusuf Özkay, Zafer Asım Kaplancıklı

TL;DR
This study synthesized new benzimidazole-thiadiazole compounds and found some to be effective against fungi and bacteria, with low toxicity.
Contribution
The paper introduces new benzimidazole-thiadiazole hybrids with potent antimicrobial activity and evaluates their reactivity and binding modes.
Findings
Compounds 5f and 5h showed potent antifungal activity against C. albicans with a MIC of 3.90 μg/mL.
Compound 5h was found to be chemically more reactive based on HOMO–LUMO analysis.
Molecular dynamics simulations showed compounds 5f and 5h to be stable in the active site of 14-α demethylase.
Abstract
In this study, a series of new benzimidazole-thiadiazole hybrids were synthesized, and the synthesized compounds were screened for their antimicrobial activities against eight species of pathogenic bacteria and three fungal species. Azithromycin, voriconazole, and fluconazole were used as reference drugs in the mtt assay. Among them, compounds 5f and 5h showed potent antifungal activity against C. albicans with a MIC of 3.90 μg/mL. Further, the results of the antimicrobial assay for compounds 5a, 5b, 5f, and 5h proved to be potent against E. faecalis (ATCC 2942) on the basis of an acceptable MIC value of 3.90 μg/mL. The cytotoxic effects of compounds that are effective as a result of their antimicrobial activity on healthy mouse fibroblast cells (L929) were evaluated. According to HOMO–LUMO analysis, compound 5h (with the lower ΔE = 3.417 eV) is chemically more reactive than the other…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical industry and healthcare · Ethics and bioethics in healthcare
